Neurovascular abnormalities in humans and mice with Huntington's disease

Experimental Neurology

Volumn 250, Issue , 2013, Pages 20-30

  Lin, Chien Yuan ^a,b   Hsu, Yi Hua ^a,b   Lin, Ming Huang ^a,b   Yang, Tsai Hui ^a,b   Chen, Hui Mei ^a   Chen, Yu Chen ^a   Hsiao, Han Yun ^a   Chen, Chiao Chi ^a,b   Chern, Yijuang ^a   Chang, Chen ^a,b  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b ACADEMIA SINICA   (Taiwan)

Author keywords

Cerebral blood volume; Huntington's disease; Microscopic magnetic resonance angiography; Microvasculature; Vessel density

Indexed keywords

COLLAGEN TYPE 4; GADOLINIUM PENTETATE MEGLUMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BRAIN BLOOD VOLUME; BRAIN CORTEX; CAPILLARY DENSITY; CAUDATE NUCLEUS; CEREBROVASCULAR DISEASE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE ANGIOGRAPHY; MICROVASCULATURE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; PUTAMEN; SUBSTANTIA NIGRA; THREE DIMENSIONAL IMAGING;

CEREBRAL BLOOD VOLUME; HUNTINGTON'S DISEASE; MICROSCOPIC MAGNETIC RESONANCE ANGIOGRAPHY; MICROVASCULATURE; VESSEL DENSITY;

ADULT; AGED; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HUNTINGTON DISEASE; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MICE; MICROVESSELS; MIDDLE AGED;

EID: 84885746892     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.08.019     Document Type: Article

References (51)

1. Aktas O., Ullrich O., Infante-Duarte C., Nitsch R., Zipp F. Neuronal damage in brain inflammation. Arch. Neurol. 2007, 64(2):185-189.
2. Argandona E.G., Bengoetxea H., Ortuzar N., Bulnes S., Rico-Barrio I., Lafuente J.V. Vascular endothelial growth factor: adaptive changes in the neuroglialvascular unit. Curr. Neurovasc. Res. 2012, 9(1):72-81.
3. Backman L., Robins-Wahlin T.B., Lundin A., Ginovart N., Farde L. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain 1997, 120(Pt 12):2207-2217.
4. Beck H., Plate K.H. Angiogenesis after cerebral ischemia. Acta Neuropathol. 2009, 117(5):481-496.
5. Biron K.E., Dickstein D.L., Gopaul R., Jefferies W.A. Amyloid triggers extensive cerebral angiogenesis causing blood brain barrier permeability and hypervascularity in Alzheimer's disease. PLoS One 2011, 6(8):e23789.
6. Boxerman J.L., Hamberg L.M., Rosen B.R., Weisskoff R.M. MR contrast due to intravascular magnetic susceptibility perturbations. Magn. Reson. Med. 1995, 34(4):555-566.
7. Carmeliet P. Blood vessels and nerves: common signals, pathways and diseases. Nat. Rev. Genet. 2003, 4(9):710-720.
8. Carmeliet P., Storkebaum E. Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin. Cell Dev. Biol. 2002, 13(1):39-53.
9. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci. 1999, 19(8):3248-3257.
10. Cepeda-Prado E., Popp S., Khan U., Stefanov D., Rodriguez J., Menalled L.B., Dow-Edwards D., Small S.A., Moreno H. R6/2 Huntington's disease mice develop early and progressive abnormal brain metabolism and seizures. J. Neurosci. 2012, 32(19):6456-6467.
11. Chantrain C.F., DeClerck Y.A., Groshen S., McNamara G. Computerized quantification of tissue vascularization using high-resolution slide scanning of whole tumor sections. J. Histochem. Cytochem. 2003, 51(2):151-158.
12. Chen J.J., Salat D.H., Rosas H.D. Complex relationships between cerebral blood flow and brain atrophy in early Huntington's disease. NeuroImage 2012, 59(2):1043-1051.
13. Chou S.Y., Lee Y.C., Chen H.M., Chiang M.C., Lai H.L., Chang H.H., Wu Y.C., Sun C.N., Chien C.L., Lin Y.S., Wang S.C., Tung Y.Y., Chang C., Chern Y. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem. 2005, 93(2):310-320.
14. Cummings D.M., Andre V.M., Uzgil B.O., Gee S.M., Fisher Y.E., Cepeda C., Levine M.S. Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J. Neurosci. 2009, 29(33):10371-10386.
15. Desai B.S., Monahan A.J., Carvey P.M., Hendey B. Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant. 2007, 16(3):285-299.
16. Duran-Vilaregut J., del Valle J., Manich G., Camins A., Pallas M., Vilaplana J., Pelegri C. Role of matrix metalloproteinase-9 (MMP-9) in striatal blood-brain barrier disruption in a 3-nitropropionic acid model of Huntington's disease. Neuropathol. Appl. Neurobiol. 2011, 37(5):525-537.
17. Farkas E., Luiten P.G. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol. 2001, 64(6):575-611.
18. Franciosi S., Ryu J.K., Shim Y., Hill A., Connolly C., Hayden M.R., McLarnon J.G., Leavitt B.R. Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiol. Dis. 2012, 45(1):438-449.
19. Greenberg S.M. Small vessels, big problems. N. Engl. J. Med. 2006, 354(14):1451-1453.
20. Harris G.J., Codori A.M., Lewis R.F., Schmidt E., Bedi A., Brandt J. Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain 1999, 122(Pt 9):1667-1678.
21. Huang Y.C., Wu Y.R., Tseng M.Y., Chen Y.C., Hsieh S.Y., Chen C.M. Increased prothrombin, apolipoprotein A-IV, and haptoglobin in the cerebrospinal fluid of patients with Huntington's disease. PLoS One 2011, 6(1):e15809.
22. Liebner S., Plate K.H. Differentiation of the brain vasculature: the answer came blowing by the Wnt. J. Angiogenes. Res. 2010, 2:1.
23. Lin C.Y., Lin M.H., Cheung W.M., Lin T.N., Chen J.H., Chang C. In vivo cerebromicrovasculatural visualization using 3D DeltaR2-based microscopy of magnetic resonance angiography (3DDeltaR2-mMRA). NeuroImage 2009, 45(3):824-831.
24. Maat-Schieman M.L., Dorsman J.C., Smoor M.A., Siesling S., Van Duinen S.G., Verschuuren J.J., den Dunnen J.T., Van Ommen G.J., Roos R.A. Distribution of inclusions in neuronal nuclei and dystrophic neurites in Huntington disease brain. J. Neuropathol. Exp. Neurol. 1999, 58(2):129-137.
25. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87(3):493-506.
26. Meyer E.P., Ulmann-Schuler A., Staufenbiel M., Krucker T. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(9):3587-3592.
27. Miraux S., Serres S., Thiaudiere E., Canioni P., Merle M., Franconi J.M. Gadolinium-enhanced small-animal TOF magnetic resonance angiography. MAGMA 2004, 17(3-6):348-352.
28. Mironov V., Hritz M.A., LaManna J.C., Hudetz A.G., Harik S.I. Architectural alterations in rat cerebral microvessels after hypobaric hypoxia. Brain Res. 1994, 660(1):73-80.
29. Miyakawa T., Uehara Y., Desaki J., Kimura T., Kuramoto R. Morphological changes of microvessels in the brain with Alzheimer's disease. Jpn. J. Psychiatr. Neurol. 1988, 42(4):819-824.
30. Montoya A., Price B.H., Menear M., Lepage M. Brain imaging and cognitive dysfunctions in Huntington's disease. J. Psychiatr. Neurosci. 2006, 31(1):21-29.
31. Novak M.J., Tabrizi S.J. Huntington's disease. BMJ 2010, 340:c3109.
32. Ogawa S., Menon R.S., Tank D.W., Kim S.G., Merkle H., Ellermann J.M., Ugurbil K. Functional brain mapping by blood oxygenation level-dependent contrast magnetic resonance imaging. A comparison of signal characteristics with a biophysical model. Biophys. J. 1993, 64(3):803-812.
33. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010, 9(7):689-701.
34. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2004, Elsevier Academic Press.
35. Rieder M.J., O'Drobinak D.M., Greene A.S. A computerized method for determination of microvascular density. Microvasc. Res. 1995, 49(2):180-189.
36. Sawiak S.J., Wood N.I., Williams G.B., Morton A.J., Carpenter T.A. Use of magnetic resonance imaging for anatomical phenotyping of the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 2009, 33(1):12-19.
37. Sekhon L.H., Morgan M.K., Spence I. Normal perfusion pressure breakthrough: the role of capillaries. J. Neurosurg. 1997, 86(3):519-524.
38. Stenman J.M., Rajagopal J., Carroll T.J., Ishibashi M., McMahon J., McMahon A.P. Canonical Wnt signaling regulates organ-specific assembly and differentiation of CNS vasculature. Science 2008, 322(5905):1247-1250.
39. Storkebaum E., Lambrechts D., Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004, 26(9):943-954.
40. Tofts P.S., Kermode A.G. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn. Reson. Med. 1991, 17(2):357-367.
41. Tong X.K., Nicolakakis N., Kocharyan A., Hamel E. Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease. J. Neurosci. 2005, 25(48):11165-11174.
42. Tropres I., Lamalle L., Peoc'h M., Farion R., Usson Y., Decorps M., Remy C. In vivo assessment of tumoral angiogenesis. Magn. Reson. Med. 2004, 51(3):533-541.
43. Vis J.C., Nicholson L.F., Faull R.L., Evans W.H., Severs N.J., Green C.R. Connexin expression in Huntington's diseased human brain. Cell Biol. Int. 1998, 22(11-12):837-847.
44. Wolf R.C., Gron G., Sambataro F., Vasic N., Wolf N.D., Thomann P.A., Saft C., Landwehrmeyer G.B., Orth M. Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease. J. Cereb. Blood Flow Metab. 2011, 31(9):1908-1918.
45. Wu E.X., Wong K.K., Andrassy M., Tang H. High-resolution in vivo CBV mapping with MRI in wild-type mice. Magn. Reson. Med. 2003, 49(4):765-770.
46. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407(6801):242-248.
47. Zacchigna S., Lambrechts D., Carmeliet P. Neurovascular signalling defects in neurodegeneration. Nat. Rev. Neurosci. 2008, 9(3):169-181.
48. Zacharoff L., Tkac I., Song Q., Tang C., Bolan P.J., Mangia S., Henry P.G., Li T., Dubinsky J.M. Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease. J. Cereb. Blood Flow Metab. 2012, 32(3):502-514.
49. Zhang J., Peng Q., Li Q., Jahanshad N., Hou Z., Jiang M., Masuda N., Langbehn D.R., Miller M.I., Mori S., Ross C.A., Duan W. Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images. NeuroImage 2010, 49(3):2340-2351.
50. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 2005, 28(4):202-208.
51. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57(2):178-201.